Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain

May 24, 2011 By Bio-Medicine.Org

NORTH LIBERTY, Iowa, May 24, 2011 /PRNewswire/ — KemPharm, Inc.
today announced positive results from a Phase 1 clinical trial of
its most advanced opioid-based drug candidate, KP201, a novel
hydrocodone prodrug for treating pain.  KP201 is a new
chemical entity (NCE) composed of hydrocodone chemically bound to a
ligand.

The data confirmed that KP201 is cleaved in man as predicted,
releasing the active pharmaceutical compound hydrocodone into the
bloodstream at amounts equivalent to the reference listed drug
(RLD), Norco®.  Importantly, intact KP201 could not be
detected in systemic circulation, indicating that minimal
additional studies are warranted to determine the impact of KP201
exposure in the body.

“Our findings from this first clinical trial of KP201 are as
good as we could have hoped,” stated Sven Guenther, Ph.D., Vice
President of Research at KemPharm. “The human pharmacokinetic
profile of KP201 indicates that the prodrug releases hydrocodone
efficiently and is bioequivalent to the comparator drug, supporting
a 505(b)(2) regulatory pathway for KP201 in combination with
acetaminophen. KP201 has unique physiochemical and pharmacological
attributes that deliver additional patient benefits, including
reduced potential for abuse as well as reduction or elimination of
opioid-induced constipation.”

The Phase 1 study was a single dose, three-treatment,
three-period, six-sequence, cross-over PK study in which
twenty-four healthy volunteers received oral doses of 5 mg KP201,
10 mg KP201, or 10/325 mg tablet of hydrocodone bitartrate and
acetaminophen (Norco®, RLD).  The objectives of the study
included evaluation of the serum concentrations of hydrocodone,
certain metabolites, and intact KP201, as well as safety and
tolerability.

“We believe KP201 has the potential to assume sizeable market
share, given the opportunity for extended market exclusivity in
acute and chronic pain, as well as the potential to mi

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech